Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
CareDx, Inc. logo — Creating life-changing solutions that enable transplant pati...

CareDx, Inc.

Creating life-changing solutions that enable transplant patients to thrive.

Founded 1998 United States Brisbane, United States 812 employees Post Ipo Equity Total: $508.64M Biotechnology, Health Care +1

General Information

Company Name CareDx, Inc.
Founded Year 1998
Location United States Brisbane, United States +1
Employees 812
Industries Biotechnology, Health Care, Information Technology
Funding Stage Post Ipo Equity
Social

Get notified when CareDx, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About CareDx, Inc.

CareDx, Inc. is a biotechnology company dedicated to revolutionizing transplant patient care through innovative surveillance management solutions. Their focus on non-invasive diagnostics, leveraging genomics and bioinformatics technology along with robust clinical evidence, positions them as a leader in organ transplant surveillance and pre-transplant HLA typing solutions. One of their pioneering offerings is AlloSure, a non-invasive blood test that measures allograft injury and identifies the probability of active rejection in kidney transplant patients. This proprietary Next-Generation Sequencing (NGS) based test is analytically validated and outperforms traditional methods like serum creatinine, demonstrating high accuracy and precision in detecting active rejection. Additionally, CareDx provides AlloMap Molecular Expression Testing for heart transplant recipients, aiding in the identification of patients with stable allograft function and low probability of acute cellular rejection. This testing, available since 2005, has received clearances and marks from regulatory bodies and is integrated into international guidelines for heart transplant patient care. Founded in 1998 and headquartered in the United States, the company attracted a $164.00M Post-IPO Equity investment in January 2021, indicating strong investor confidence in their innovative solutions for improving transplant patient outcomes. CareDx's commitment to leveraging advanced technology to address critical needs in transplant patient care positions them as a key player in the intersection of biotechnology, healthcare, and information technology.

Taxonomy: organ transplant, transplant patients, genomics technology, bioinformatics technology, clinical evidence, surveillance solutions, HLA typing solutions, Next-Generation Sequencing, organ injury, donor-derived cell-free DNA, kidney transplant recipients, heart transplant recipients, AlloMap Molecular Expression Testing, non-invasive diagnostics, transplant patient care

Funding Rounds & Investors (15)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 21 Jan 2021
Post-IPO Equity •••••• - 09 Jun 2020
Post-IPO Equity •••••• - 13 Nov 2018
Post-IPO Equity •••••• - 05 Oct 2017
Post-IPO Debt •••••• - 15 Mar 2017

View All 15 Funding Rounds

CareDx, Inc. Alternatives & Competitors

CareDx, Inc. vs
TransMedics, Inc.
TransMedics, Inc. United States

Redefining what's possible in organ transplantation

Post Ipo Debt
478 employees
Health Care, Health and Wellness
Compare CareDx, Inc. vs TransMedics, Inc.
CareDx, Inc. vs
Valeos
Valeos United States

Valeos is part of Transplants.org, Inc., a 501(c)(3) nonprofit improving outcomes and access for tra...

11 employees
Health Care, Health and Wellness
CareDx, Inc. vs
Gift of Life Howie's House
Gift of Life Howie's House United States

A “home away from home” for organ transplant patients and their families traveling to Philadelphia f...

20 employees
Health Care, Hospitality
Compare CareDx, Inc. vs Gift of Life Howie's House
Also compare with: CareDx, Inc. vs Buckeye Transplant Services Buckeye Transplant Services

FAQ About CareDx, Inc.

Creating life-changing solutions that enable transplant patients to thrive.
CareDx, Inc. was founded in 1998.
CareDx, Inc. is headquartered in Brisbane, United States.
CareDx, Inc. operates in the following industries: Biotechnology, Health Care, Information Technology.
CareDx, Inc. has approximately 812 employees.
CareDx, Inc. has completed 15 funding rounds, raising a total of $508.64M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to CareDx, Inc. include TransMedics, Inc., Valeos, Gift of Life Howie's House, Buckeye Transplant Services, Medeor Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CareDx, Inc. and TransMedics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors CareDx, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy